Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.
Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the challenges of managing immune-related toxicities in melanoma.
Although the advent of immunotherapy has transformed the treatment landscape in melanoma, these therapies are not without risk of immune-related toxicities. For example, immunotherapy can cause gastrointestinal toxicities, such as colitis, enteritis, hepatitis, and liver function test abnormalities, as well as endocrine disorders, Sznol says.
Less common toxicities include myositis, myocarditis, and myasthenia gravis, explains Sznol. Moreover, some patients may experience a combination of these more unusual adverse effects (AEs).
It is important to inform patients of these potential AEs, develop an understanding of how to best manage these toxicities, and consult with others if additional help is required to mitigate these conditions, concludes Sznol.
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab
2 Commerce Drive
Cranbury, NJ 08512